+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A double blind multicenter trial of piroxicam and naproxen in osteoarthritis



A double blind multicenter trial of piroxicam and naproxen in osteoarthritis



Clinical Rheumatology 5(1): 84-91



A multicentre, double-blind study of unprecedented size was conducted to compare the safety and efficacy of piroxicam and naproxen in the treatment of osteoarthritis. The study comprised 2,035 patients and a treatment period of 12 weeks. The dosage was 20 mg piroxicam and 750 mg naproxen daily with the option to reduce to 10 and 500 mg, respectively, at week 4 or 8. No major difference between the drugs was observed with regard to overall incidence of adverse events. The frequency of serious adverse events was about 1% for both drugs. A statistically significant decline of adverse events was about 1% for both drugs. A statistically significant decline of adverse events with age was found in both sexes. Piroxicam was significantly superior to naproxen for pain at rest and pain on movement at 12 weeks and degree of restriction in daily activity at 4 weeks. A significantly increasing beneficial effect was observed with both drugs between 4 and 12 weeks of treatment. The comparable safety observed for the two drugs is in contrast to perceptions based on spontaneous reports to official monitoring systems.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 004572182

Download citation: RISBibTeXText

PMID: 3514082


Related references

Piroxicam and naproxen in osteoarthritis a double blind comparative multicenter trial carried out in general practice. Tidsskrift for den Norske Laegeforening 106(30): 2487-2492, 2559, 1986

Double blind crossover trial of piroxicam and naproxen in the treatment of osteoarthritis of hip and knee. British Journal of Clinical Practice 35(1): 45-50, 1981

Multicentric double blind clinical trial with naproxen 1000 mg versus piroxicam 20 mg once a day morning dosage in the treatment of knee osteoarthritis. Folha Medica 98(4): 269-272, 1989

A randomized, double-blind, multicenter trial of nimesulide-beta-cyclodextrin versus naproxen in patients with osteoarthritis. Clinical Therapeutics 24(4): 504-519, 2002

A double-blind crossover evaluation of naproxen and piroxicam in osteoarthritis of hip or knee. Journal of International Medical Research 13(5): 263-269, 1985

Double-blind crossover comparison of piroxicam and naproxen in the treatment of active osteoarthritis. Seminars in Arthritis and Rheumatism 14(3 Suppl 1): 3-6, 1985

A double blind crossover multicenter study of piroxicam and naproxen in rheumatoid arthritis. Current Therapeutic Research 44(6): 1058-1070, 1988

Piroxicam and naproxen in arthrosis. A double-blind, comparative multicenter study in general practice. Tidsskrift for den Norske Laegeforening 106(30): 2487-2492, 1986

Comparison of piroxicam with naproxen in rheumatoid arthritis a double blind crossover multicenter study. European Journal of Rheumatology & Inflammation 4(3): 318-322, 1981

Treatment of acute musculoskeletal disorders with piroxicam results of a double blind multicenter comparison with naproxen. Current Therapeutic Research 42(5): 974-987, 1987

Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Annals of the Rheumatic Diseases 52(12): 881-885, 1993

Comparison of naproxen and piroxicam in rheumatoid arthritis and Bechterew's syndrome. A double-blind parallel multicenter study. Tidsskrift for den Norske Laegeforening 106(17-18): 1485-1487, 1986

Comparison of naproxen with piroxicam in rheumatoid arthritis and ankylosing spondylitis a double blind parallel multicenter study. Tidsskrift for den Norske Laegeforening 106(17-18): 1485-1487, 1517, 1986

Efficacy and tolerability of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis: a double-blind comparison with standard naproxen followed by an open-label trial. Current Medical Research and Opinion 12(10): 640-651, 1992

Piroxicam vs indomethacin: a double blind multicenter comparative study in osteoarthritis. A Canadian Multicenter Study. Journal of Rheumatology 12(2): 328-336, 1985